Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 randomized open-label renal function comparison of Stribild and other tenofovir DF-containing regimens in treatment-naive adults with HIV-1
2014-002095-93Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil, atazanavir, ritonavir, emtricitabine, tenofovir disoproxil fumarate and 3 more in Human immunodeficiency virus infection type 1 (4 arms), sponsored by Gilead Sciences. Primary endpoint: Actual glomerular filtration rate at Week 24. Started Jul 2014; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxilatazanavirritonaviremtricitabinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-002095-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002095-93.